Mod Rheumatol. 2023 doi: 10.1093/mr/road059 Epub ahead of print
Pots hoc analysis of peficitinib phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.
Approved as a treatment for patients with RA and an inadequate response to current therapies, in Japan, Korea, and Taiwan, peficitinib’s clinical efficacy and safety has been established in two previous Phase 3 trials. However, data are currently limited regarding the proportion of patients who continue to achieve remission after having achieved remission or LDA earlier in the treatment regimen.
To help address this, Tanaka, et al. evaluated the persistence of remission over the study period, and the relationship between patient demographics/baseline characteristics and remission rate.